Search

Your search keyword '"EARLY BILATERAL OOPHORECTOMY"' showing total 4 results
Start Over Descriptor "EARLY BILATERAL OOPHORECTOMY" Database OpenAIRE
4 results on '"EARLY BILATERAL OOPHORECTOMY"'

1. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

Subjects
WIDE ASSOCIATION ANALYSIS, endocrine system diseases, IDENTIFICATION, MORTALITY, SUSCEPTIBILITY ALLELES, LOCUS, WOMEN, MODIFIERS, COHORT, FUNCTIONAL VARIANTS, skin and connective tissue diseases, EARLY BILATERAL OOPHORECTOMY
Abstract

Background: Genome-wide association studies (GWAS) have identified 94 common single-nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 associated with ovarian cancer (OC) risk. Several of these are also associated with risk of BC or OC for women who carry a pathogenic mutation in the high-risk BC and OC genes BRCA1 or BRCA2. The combined effects of these variants on BC or OC risk for BRCA1 and BRCA2 mutation carriers have not yet been assessed while their clinical management could benefit from improved personalized risk estimates. Methods: We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]-positive, and ER-negative) and for OC. Using data from 15 252 female BRCA1 and 8211 BRCA2 carriers, the association of each PRS with BC or OC risk was evaluated using a weighted cohort approach, with time to diagnosis as the outcome and estimation of the hazard ratios (HRs) per standard deviation increase in the PRS. Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2 x 10(53)). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2 x 10(-20)). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS. Conclusions: BC and OC PRS are predictive of cancer risk in BRCA1 and BRCA2 carriers. Incorporation of the PRS into risk prediction models has promise to better inform decisions on cancer risk management.

Published
2017

2. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

Subjects
WIDE ASSOCIATION ANALYSIS, IDENTIFICATION, MORTALITY, SUSCEPTIBILITY ALLELES, LOCUS, WOMEN, MODIFIERS, COHORT, FUNCTIONAL VARIANTS, EARLY BILATERAL OOPHORECTOMY
Abstract

Background: Genome-wide association studies (GWAS) have identified 94 common single-nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 associated with ovarian cancer (OC) risk. Several of these are also associated with risk of BC or OC for women who carry a pathogenic mutation in the high-risk BC and OC genes BRCA1 or BRCA2. The combined effects of these variants on BC or OC risk for BRCA1 and BRCA2 mutation carriers have not yet been assessed while their clinical management could benefit from improved personalized risk estimates.Methods: We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]-positive, and ER-negative) and for OC. Using data from 15 252 female BRCA1 and 8211 BRCA2 carriers, the association of each PRS with BC or OC risk was evaluated using a weighted cohort approach, with time to diagnosis as the outcome and estimation of the hazard ratios (HRs) per standard deviation increase in the PRS.Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2 x 10(53)). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2 x 10(-20)). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS.Conclusions: BC and OC PRS are predictive of cancer risk in BRCA1 and BRCA2 carriers. Incorporation of the PRS into risk prediction models has promise to better inform decisions on cancer risk management.

Published
2017

3. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

Author

Kuchenbaecker, Karoline B., McGuffog, Lesley, Barrowdale, Daniel, Lee, Andrew, Soucy, Penny, Dennis, Joe, Domchek, Susan M., Robson, Mark, Spurdle, Amanda B., Ramus, Susan J., Mavaddat, Nasim, Terry, Mary Beth, Neuhausen, Susan L., Schmutzler, Rita Katharina, Simard, Jacques, Pharoah, Paul D. P., Offit, Kenneth, Couch, Fergus J., Chenevix-Trench, Georgia, Easton, Douglas F., Antoniou, Antonis C., Oosterwijk, Jan, Targeted Gynaecologic Oncology (TARGON), and Damage and Repair in Cancer Development and Cancer Treatment (DARE)

Subjects
WIDE ASSOCIATION ANALYSIS, endocrine system diseases, IDENTIFICATION, MORTALITY, SUSCEPTIBILITY ALLELES, LOCUS, WOMEN, MODIFIERS, COHORT, FUNCTIONAL VARIANTS, skin and connective tissue diseases, EARLY BILATERAL OOPHORECTOMY
Abstract

Background: Genome-wide association studies (GWAS) have identified 94 common single-nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 associated with ovarian cancer (OC) risk. Several of these are also associated with risk of BC or OC for women who carry a pathogenic mutation in the high-risk BC and OC genes BRCA1 or BRCA2. The combined effects of these variants on BC or OC risk for BRCA1 and BRCA2 mutation carriers have not yet been assessed while their clinical management could benefit from improved personalized risk estimates. Methods: We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]-positive, and ER-negative) and for OC. Using data from 15 252 female BRCA1 and 8211 BRCA2 carriers, the association of each PRS with BC or OC risk was evaluated using a weighted cohort approach, with time to diagnosis as the outcome and estimation of the hazard ratios (HRs) per standard deviation increase in the PRS. Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2 x 10(53)). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2 x 10(-20)). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS. Conclusions: BC and OC PRS are predictive of cancer risk in BRCA1 and BRCA2 carriers. Incorporation of the PRS into risk prediction models has promise to better inform decisions on cancer risk management.

Published
2017

4. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers

Author

Kuchenbaecker, Karoline B., Lesley, Mcguffog, Daniel, Barrowdale, Andrew, Lee, Penny, Soucy, Sue, Healey, Joe, Dennis, Michael, Lush, Mark, Robson, Spurdle, Amanda B., Ramus, Susan J., Nasim, Mavaddat, Mary Beth Terry, Neuhausen, Susan L., Ute, Hamann, Melissa, Southey, John, Esther M., Chung, Wendy K., Daly, Mary B., Buys, Saundra S., Goldgar, David E., Dorfling, Cecilia M., van Rensburg, Elizabeth J., Yuan Chun Ding, Bent, Ejlertsen, Anne-Marie, Gerdes, Hansen, Thomas V. O., Susan, Slager, Emily, Hallberg, Javier, Benitez, Ana, Osorio, Nancy, Cohen, William, Lawler, Weitzel, Jeffrey N., Paolo, Peterlongo, Valeria, Pensotti, Riccardo, Dolcetti, Monica, Barile, Bernardo, Bonanni, Jacopo, Azzollini, Siranoush, Manoukian, Bernard, Peissel, Paolo, Radice, Antonella, Savarese, Papi, Laura, Giannini, Giuseppe, Florentia, Fostira, Irene, Konstantopoulou, Julian, Adlard, Carole, Brewer, Jackie, Cook, Rosemarie, Davidson, Diana, Eccles, Ros, Eeles, Steve, Ellis, Embrace, Debra, Frost, Shirley, Hodgson, Louise, Izatt, Fiona, Lalloo, Kai-ren, Ong, Godwin, Andrew K., Norbert, Arnold, Bernd, Dworniczak, Christoph, Engel, Andrea, Gehrig, Eric, Hahnen, Jan, Hauke, Karin, Kast, Alfons, Meindl, Dieter, Niederacher, Rita Katharina Schmutzler, Raymonda, Varon-Mateeva, Shan, Wang-Gohrke, Barbara, Wappenschmidt, Laure, Barjhoux, Marie-Agne`s, Collonge-Rame, Camille, Elan, GEMO Study Collaborators, Lisa, Golmard, Emmanuelle, Barouk-Simonet, Fabienne, Lesueur, Sylvie, Mazoyer, Joanna, Sokolowska, Dominique Stoppa- Lyonnet, Claudine, Isaacs, Claes, Kathleen B. M., Bruce, Poppe, Miguel de la Hoya, Vanesa, Garcia-Barberan, Kristiina, Aittom€aki, Heli, Nevanlinna, Ausems, Margreet G. E. M., de Lange, J. L., Gomez Garcia, Encarna B., Hebon, Hogervorst, Frans B. L., Kets, Carolien M., Meijers-Heijboer, Hanne E. J., Oosterwijk, Jan C., Rookus, Matti A., van Asperen, Christi J., van den Ouweland, Ans M. W., van Doorn, Helena C., van Os, Theo A. M., Ava, Kwong, Edith, Olah, Orland, Diez, Joan, Brunet, Conxi, Lazaro, Alex, Teule´, Jacek, Gronwald, Anna, Jakubowska, Katarzyna, Kaczmarek, Jan, Lubinski, Grzegorz, Sukiennicki, Barkardottir, Rosa B., Jocelyne, Chiquette, Simona, Agata, Marco, Montagna, Teixeira, Manuel R., Kconfab, Investigators, Sue Kyung Park, Curtis, Olswold, Marc, Tischkowitz, Lenka, Foretova, Pragna, Gaddam, Joseph, Vijai, Georg, Pfeiler, Christine, Rappaport-Fuerhauser, Singer, Christian F., Tea, Muy-Kheng M., Greene, Mark H., Loud, Jennifer T., Gad, Rennert, Imyanitov, Evgeny N., Hulick, Peter J., Hays, John L., Marion, Piedmonte, Rodriguez, Gustavo C., Julie, Martyn, Gord, Glendon, Anna Marie Mulligan, Andrulis, Irene L., Amanda Ewart Toland, Uffe Birk Jensen, Kruse, Torben A., Inge Sokilde Pedersen, Mads, Thomassen, Caligo, Maria A., Soo-Hwang, Teo, Raanan, Berger, Eitan, Friedman, Yael, Laitman, Brita, Arver, Ake, Borg, Hans, Ehrencrona, Johanna, Rantala, Olopade, Olufunmilayo I., Ganz, Patricia A., Nussbaum, Robert L., Bradbury, Angela R., Domchek, Susan M., Nathanson, Katherine L., Arun, Banu K., Paul, James, Karlan, Beth Y., Jenny, Lester, Jacques, Simard, Pharoah, Paul D. P., Kenneth, Offit, Couch, Fergus J., Georgia, Chenevix-Trench, Easton, Douglas F., and Antoniou, Antonis C.

Subjects
Adult, Cancer Research, Heterozygote, Multifactorial Inheritance, Adolescent, Breast Neoplasms, Female, Genetic Predisposition to Disease, Humans, Middle Aged, Ovarian Neoplasms, Polymorphism, Single Nucleotide, Prognosis, Proportional Hazards Models, Receptors, Estrogen, Risk Assessment, Risk Factors, Young Adult, Genes, BRCA1, Genes, BRCA2, Mutation, Oncology, endocrine system diseases, SUSCEPTIBILITY ALLELES, MODIFIERS, Article, Receptors, Medicine and Health Sciences, LOCUS, COHORT, Polymorphism, FUNCTIONAL VARIANTS, skin and connective tissue diseases, EARLY BILATERAL OOPHORECTOMY, IDENTIFICATION, MORTALITY, Biology and Life Sciences, WOMEN, Single Nucleotide, BRCA1, Estrogen, BRCA2, WIDE ASSOCIATION ANALYSIS, Genes
Abstract

Background: Genome-wide association studies (GWAS) have identified 94 common single-nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 associated with ovarian cancer (OC) risk. Several of these are also associated with risk of BC or OC for women who carry a pathogenic mutation in the high-risk BC and OC genes BRCA1 or BRCA2. The combined effects of these variants on BC or OC risk for BRCA1 and BRCA2 mutation carriers have not yet been assessed while their clinical management could benefit from improved personalized risk estimates. Methods: We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]-positive, and ER-negative) and for OC. Using data from 15 252 female BRCA1 and 8211 BRCA2 carriers, the association of each PRS with BC or OC risk was evaluated using a weighted cohort approach, with time to diagnosis as the outcome and estimation of the hazard ratios (HRs) per standard deviation increase in the PRS. Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2 x 10(53)). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2 x 10(-20)). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS. Conclusions: BC and OC PRS are predictive of cancer risk in BRCA1 and BRCA2 carriers. Incorporation of the PRS into risk prediction models has promise to better inform decisions on cancer risk management.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results